Madrigal Pharmaceuticals MDGL shares soared 10.9% on Wednesday. The uptrend was observed after the U.S. Patent and Trademark ...

World IP Review is set to host the highly anticipated AI and IP USA 2025, a one-day event on October 9, 2025 in New York. The ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

You successfully represented Regeneron Pharmaceuticals Inc. in Regeneron Pharmaceuticals Inc. v. Mylan Pharmaceuticals, Inc., in which the US District Court for the Northern District of West Virginia ...

Federal Circuit decision in appeal from Regeneron Pharms., Inc. addresses issues of personal jurisdiction, preliminary injunctions, and biopharmaceutical patent vali ...

Regeneron Pharmaceuticals has settled allegations that it misused a patented protein to test its COVID-19 treatment REGEN-COV, according to filings in New York federal court.

Regeneron Pharmaceuticals. has been granted a patent for methods and systems to detect abnormal karyotypes. The approach involves sequencing samples, generating quality control metrics, and analyzing ...

On July 16, 2024, the UPC issued its first-ever revocation judgment, invalidating a key patent owned by Amgen Inc. Back in June 2023, Amgen filed an infringement action against Regeneron ...

However, IP challenges or patent expirations will bring generic encroachment, affecting Regeneron's revenue streams. As with many healthcare companies, Regeneron faces these IP threats.